Ganesh Raghu1, Athol U Wells2, Andrew G Nicholson2, Luca Richeldi3, Kevin R Flaherty4, Florence Le Maulf5, Susanne Stowasser6, Rozsa Schlenker-Herceg7, David M Hansell2. 1. 1 Department of Medicine, University of Washington, Seattle, Washington. 2. 2 Royal Brompton and Harefield NHS Foundation Trust and National Heart and Lung Institute, Imperial College, London, United Kingdom. 3. 3 National Institute for Health Research Southampton Respiratory Biomedical Research Unit and Clinical and Experimental Sciences, University of Southampton, Southampton, United Kingdom. 4. 4 University of Michigan Health System, Ann Arbor, Michigan. 5. 5 Boehringer Ingelheim France S.A.S., Reims, France. 6. 6 Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany; and. 7. 7 Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut.
Abstract
RATIONALE: In the absence of a surgical lung biopsy, patients diagnosed with idiopathic pulmonary fibrosis (IPF) in clinical practice could participate in the INPULSIS trials of nintedanib if they had honeycombing and/or traction bronchiectasis plus reticulation, without atypical features of usual interstitial pneumonia (UIP), on high-resolution computed tomography (HRCT). Thus, the patients in these trials represented patients with definite UIP and a large subgroup of patients with possible UIP. OBJECTIVES: To investigate the potential impact of diagnostic subgroups on the progression of IPF and the effect of nintedanib. METHODS: We conducted a post hoc subgroup analysis of patients with honeycombing on HRCT and/or confirmation of UIP by biopsy versus patients without either, using pooled data from the INPULSIS trials. MEASUREMENTS AND MAIN RESULTS: Seven hundred twenty-three (68.1%) patients had honeycombing and/or biopsy, and 338 (31.9%) patients had no honeycombing or biopsy. In these subgroups, respectively, the adjusted annual rate of decline in FVC in patients treated with placebo was -225.7 and -221.0 ml/yr, and the nintedanib versus placebo difference in the adjusted annual rate of decline in FVC was 117.0 ml/yr (95% confidence interval, 76.3-157.8) and 98.9 ml/yr (95% confidence interval, 36.4-161.5). There was no significant treatment-by-subgroup interaction (P = 0.8139). Adverse events were similar between the subgroups. CONCLUSIONS: Patients with IPF diagnosed in clinical practice who had possible UIP with traction bronchiectasis on HRCT and had not undergone surgical lung biopsy had disease that progressed in a similar way, and responded similarly to nintedanib, to that of patients with honeycombing on HRCT and/or confirmation of UIP by biopsy.
RATIONALE: In the absence of a surgical lung biopsy, patients diagnosed with idiopathic pulmonary fibrosis (IPF) in clinical practice could participate in the INPULSIS trials of nintedanib if they had honeycombing and/or traction bronchiectasis plus reticulation, without atypical features of usual interstitial pneumonia (UIP), on high-resolution computed tomography (HRCT). Thus, the patients in these trials represented patients with definite UIP and a large subgroup of patients with possible UIP. OBJECTIVES: To investigate the potential impact of diagnostic subgroups on the progression of IPF and the effect of nintedanib. METHODS: We conducted a post hoc subgroup analysis of patients with honeycombing on HRCT and/or confirmation of UIP by biopsy versus patients without either, using pooled data from the INPULSIS trials. MEASUREMENTS AND MAIN RESULTS: Seven hundred twenty-three (68.1%) patients had honeycombing and/or biopsy, and 338 (31.9%) patients had no honeycombing or biopsy. In these subgroups, respectively, the adjusted annual rate of decline in FVC in patients treated with placebo was -225.7 and -221.0 ml/yr, and the nintedanib versus placebo difference in the adjusted annual rate of decline in FVC was 117.0 ml/yr (95% confidence interval, 76.3-157.8) and 98.9 ml/yr (95% confidence interval, 36.4-161.5). There was no significant treatment-by-subgroup interaction (P = 0.8139). Adverse events were similar between the subgroups. CONCLUSIONS:Patients with IPF diagnosed in clinical practice who had possible UIP with traction bronchiectasis on HRCT and had not undergone surgical lung biopsy had disease that progressed in a similar way, and responded similarly to nintedanib, to that of patients with honeycombing on HRCT and/or confirmation of UIP by biopsy.
Authors: David A Lynch; J David Godwin; Sharon Safrin; Karen M Starko; Phil Hormel; Kevin K Brown; Ganesh Raghu; Talmadge E King; Williamson Z Bradford; David A Schwartz; W Richard Webb Journal: Am J Respir Crit Care Med Date: 2005-05-13 Impact factor: 21.405
Authors: Simon L F Walsh; Nicola Sverzellati; Anand Devaraj; Gregory J Keir; Athol U Wells; David M Hansell Journal: Thorax Date: 2013-10-14 Impact factor: 9.139
Authors: Christopher J Ryerson; Thomas H Urbania; Luca Richeldi; Joshua J Mooney; Joyce S Lee; Kirk D Jones; Brett M Elicker; Laura L Koth; Talmadge E King; Paul J Wolters; Harold R Collard Journal: Eur Respir J Date: 2012-12-06 Impact factor: 16.671
Authors: Kevin R Flaherty; Talmadge E King; Ganesh Raghu; Joseph P Lynch; Thomas V Colby; William D Travis; Barry H Gross; Ella A Kazerooni; Galen B Toews; Qi Long; Susan Murray; Vibha N Lama; Steven E Gay; Fernando J Martinez Journal: Am J Respir Crit Care Med Date: 2004-07-15 Impact factor: 21.405
Authors: Nicola Sverzellati; David A Lynch; David M Hansell; Takeshi Johkoh; Talmadge E King; William D Travis Journal: Radiographics Date: 2015-10-09 Impact factor: 5.333
Authors: Luca Richeldi; Roland M du Bois; Ganesh Raghu; Arata Azuma; Kevin K Brown; Ulrich Costabel; Vincent Cottin; Kevin R Flaherty; David M Hansell; Yoshikazu Inoue; Dong Soon Kim; Martin Kolb; Andrew G Nicholson; Paul W Noble; Moisés Selman; Hiroyuki Taniguchi; Michèle Brun; Florence Le Maulf; Mannaïg Girard; Susanne Stowasser; Rozsa Schlenker-Herceg; Bernd Disse; Harold R Collard Journal: N Engl J Med Date: 2014-05-18 Impact factor: 91.245
Authors: Lutz Wollin; Eva Wex; Alexander Pautsch; Gisela Schnapp; Katrin E Hostettler; Susanne Stowasser; Martin Kolb Journal: Eur Respir J Date: 2015-03-05 Impact factor: 16.671
Authors: Ayodeji Adegunsoye; Justin M Oldham; Jonathan H Chung; Steven M Montner; Cathryn Lee; Leah J Witt; Danielle Stahlbaum; Rene S Bermea; Lena W Chen; Scully Hsu; Aliya N Husain; Imre Noth; Rekha Vij; Mary E Strek; Matthew Churpek Journal: Chest Date: 2017-09-28 Impact factor: 9.410
Authors: Lorriana E Leard; Are M Holm; Maryam Valapour; Allan R Glanville; Sandeep Attawar; Meghan Aversa; Silvia V Campos; Lillian M Christon; Marcelo Cypel; Göran Dellgren; Matthew G Hartwig; Siddhartha G Kapnadak; Nicholas A Kolaitis; Robert M Kotloff; Caroline M Patterson; Oksana A Shlobin; Patrick J Smith; Amparo Solé; Melinda Solomon; David Weill; Marlies S Wijsenbeek; Brigitte W M Willemse; Selim M Arcasoy; Kathleen J Ramos Journal: J Heart Lung Transplant Date: 2021-07-24 Impact factor: 13.569
Authors: Fernando J Martinez; Alison Chisholm; Harold R Collard; Kevin R Flaherty; Jeffrey Myers; Ganesh Raghu; Simon L F Walsh; Eric S White; Luca Richeldi Journal: Lancet Respir Med Date: 2016-12-06 Impact factor: 30.700
Authors: Grace Hyun J Kim; Stephan S Weigt; John A Belperio; Matthew S Brown; Yu Shi; Joshua H Lai; Jonathan G Goldin Journal: Eur Radiol Date: 2019-08-26 Impact factor: 5.315